Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Depression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,476 result(s) found for: Depression. Displaying page 65 of 74.
    «« First « Previous 61  62  63  64  65  66  67  68  69  Next» Last»»
    EudraCT Number: 2004-001960-30 Sponsor Protocol Number: CL3-16257-057 Start Date*: 2005-03-07
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4...
    Medical condition: stable angina pectoris
    Disease: Version SOC Term Classification Code Term Level
    7.0 10002383 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NO (Completed) SE (Completed) SK (Completed) CZ (Completed) GB (Completed) IT (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003475-13 Sponsor Protocol Number: A1281148 Start Date*: 2006-12-08
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECT...
    Medical condition: Schizophrenia and Schizoaffective Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039635 Schizophrenia schizoaffective LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001433-98 Sponsor Protocol Number: N01315 Start Date*: 2008-08-11
    Sponsor Name:UCB BioSciences, Inc
    Full Title: An open-label, multinational, multicenter, follow-up study to evaluate the long-term safety and efficacy of brivaracetam, used at a flexible dose up to a maximum of 200 mg/day, in subjects aged 16 ...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SE (Completed) ES (Completed) FR (Completed) HU (Completed) FI (Prematurely Ended) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020510-29 Sponsor Protocol Number: OTR1020 Start Date*: 2010-10-08
    Sponsor Name:Purdue Pharma L.P.
    Full Title: An Open-label Study to Characterise the Pharmacokinetics and Safety of Oxycodone Hydrochloride q12h Controlled-Release Tablets (ORF) in Paediatric Patients Aged 6 to 16 Years Inclusive, Who Require...
    Medical condition: Post operative and non-surgical paediatric patients, expected to or must have moderate to severe pain requiring oral opioid analgesic treatment for at least 24 hours. Patients must be inpatient for...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002182 Analgesia LLT
    12.1 10036276 Postoperative analgesia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-003735-32 Sponsor Protocol Number: AB11005 Start Date*: 2015-04-01
    Sponsor Name:AB Science
    Full Title: A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients w...
    Medical condition: Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prohibited by CA) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002847-28 Sponsor Protocol Number: TRx-237-005 Start Date*: 2013-04-11
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer’s Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) FI (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002209-12 Sponsor Protocol Number: ABR59689 Start Date*: 2017-06-21
    Sponsor Name:Erasmus MC-Sophia Children's Hospital
    Full Title: Less opioids after major abdominal surgery in young infants using wound catheter infusion with local anesthetics: a randomized controlled trial.
    Medical condition: Children < 1 year of age undergoing major open abdominal surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10021298 Ileal atresia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10010526 Congenital large intestinal atresia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10002120 Anal atresia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10010626 Congenital small intestinal atresia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10062022 Intestinal atresia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10013812 Duodenal atresia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10028210 Multiple gastrointestinal atresias PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003369-16 Sponsor Protocol Number: GWAP19030 Start Date*: 2020-06-02
    Sponsor Name:GW Research Ltd.
    Full Title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate...
    Medical condition: Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001168-39 Sponsor Protocol Number: SNR01-NaBen Start Date*: 2019-09-23
    Sponsor Name:SyneuRx International (Taiwan) Corp
    Full Title: An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo- Controlled, Multi-Center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on ...
    Medical condition: Treatment for Schizophrenia in Adolescents
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000382-32 Sponsor Protocol Number: REP0121 Start Date*: 2021-08-16
    Sponsor Name:Dompé farmaceutici s.p.a.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastat...
    Medical condition: Cancer related fatigue in patients with locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082262 Chemotherapy fatigue LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000107-36 Sponsor Protocol Number: VER-CLBP-001 Start Date*: 2021-03-24
    Sponsor Name:Vertanical GmbH
    Full Title: Proof of efficacy, maintenance of efficacy, long-term safety and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in a multicenter study in...
    Medical condition: For the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain r...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005170-19 Sponsor Protocol Number: HP-CD-CL-2004 Start Date*: 2018-07-30
    Sponsor Name:Renishaw Neuro Solutions Ltd.
    Full Title: A Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-001982-34 Sponsor Protocol Number: MOVES Start Date*: 2022-04-19
    Sponsor Name:Pirkanmaan hyvinvointialue
    Full Title: Measuring Oncogical Value of Exercise and Statin
    Medical condition: Metastatic breast, ovarian, kidney and prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023404 Kidney cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023405 Kidney cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001205-23 Sponsor Protocol Number: OVERLORD-MS Start Date*: 2020-07-10
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)
    Medical condition: Remitting Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004006-26 Sponsor Protocol Number: RGH-MD-20 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to...
    Medical condition: Adolescent Patients (13 to 17 years of age) with Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002767-30 Sponsor Protocol Number: ACT17453 Start Date*: 2023-02-23
    Sponsor Name:Sanofi-aventis recherche & developpement
    Full Title: A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory ...
    Medical condition: Relapsed/refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004864 10086466 Relapsed/refractory multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002320-20 Sponsor Protocol Number: EFC16158 Start Date*: 2022-04-11
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry ...
    Medical condition: Fabry’s disease
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003617-18 Sponsor Protocol Number: 1439A-028 Start Date*: 2016-01-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching from ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A ...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000069-57 Sponsor Protocol Number: P15-01 Start Date*: 2017-07-21
    Sponsor Name:BIOPROJET PHARMA
    Full Title: A Multisite Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment
    Medical condition: Male or female with moderate or severe DSM-5 alcohol use disorder (based on the alcohol use disorders section of MINI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001590 Alcohol addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002763-26 Sponsor Protocol Number: 814-PM-02 Start Date*: 2019-01-17
    Sponsor Name:NeRRe Therapeutics Ltd,
    Full Title: A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, ADAPTIVE DESIGN STUDY OF THE EFFICACY, SAFETY AND PHARMACOKINETICS OF NT-814 IN FEMALE SUBJECTS WITH MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED...
    Medical condition: Hot flushes (vasomotor symptoms) in menopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10027311 Menopause flushing LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 61  62  63  64  65  66  67  68  69  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Sep 11 20:47:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA